MIRA INFORM REPORT
|
Report Date : |
30.05.2011 |
IDENTIFICATION DETAILS
|
Name : |
ENTER PHARM CO., LTD |
|
|
|
|
Registered Office : |
51, Myeongnyun 2-ga, Jongno-gu, Seoul, Korea, Zip Code 110-522 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Date of Incorporation : |
06.01.2010 |
|
|
|
|
Legal Form : |
Co., Ltd by Shares |
|
|
|
|
Line of Business : |
Wholesale of Pharmaceuticals |
RATING & COMMENTS
|
MIRA’s Rating : |
NB |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
---- |
NB |
New Business |
---- |
|
Status : |
New Company |
|
|
|
|
Payment
Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2011
|
Country Name |
Previous Rating (31.12.2010) |
Current Rating (31.03.2011) |
|
South Korea |
a1 |
a1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Basic
|
Company
Name |
ENTER PHARM CO.,
LTD. (Korean Company
Name : “(주)엔터팜”) |
|
Registered Address |
51, Myeongnyun 2-ga, Jongno-gu, Seoul,
Korea |
|
Zip Code |
110-522 |
|
Tel |
+82-2-744-0668 |
|
Fax |
+82-2-766-0668 |
|
Trading Address |
51, Myeongnyun 2-ga, Jongno-gu, Seoul, Korea |
|
Tel |
+82-2-744-0668 |
|
Fax |
+82-2-766-0668 |
|
Type |
Export |
|
Industry |
Wholesale of Pharmaceuticals |
|
Main Business |
Medicine for Injection |
|
Established (mm/dd/yyyy) |
01/06/2010 |
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
CEO’s
|
Name |
Lee Jong-Joo |
|
Address |
A-1507, 48-2, Inui-dong,
Jongno-gu, Seoul, Korea |
|
Date of Birth |
02/16/1959 |
|
Title |
President & CEO |
|
Sex |
Female |
|
Nationality |
Korean |
Profiles
|
Capital (KRW) |
50,000,000 |
|
Employees |
6 |
|
Formation |
Co., Ltd by Shares |
|
Bank Details |
Industrial Bank of Korea |
|
Corporate Registered No. |
110111-4255744 |
|
Business Registered No. |
101-86-***** (The full numbers are kept by
the National Tax Service confidentially.) |
|
Permit & Licenses |
N/A |
|
Shareholder Position |
N/A |
|
Company History |
01/06/2010 Incorporated as the present name 03/23/2011 Moved to the present HQ address
from 2nd
Fl., 8-25, Myeongnyun 2-ga, Jongno-gu, Seoul, Korea |
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
M/S. |
Lee Jong-Joo |
Female |
Korean |
08/23/2010 |
|
Director |
Mr. |
Seo Pyung-Seok |
Male |
Korean |
01/06/2010 |
|
Auditor |
Mr. |
Woo Kyung-Jin |
Male |
Korean |
01/06/2010 |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
|
|
|
The financials are not
available, and the Subject Company does not have any obligations to release its
financials to the public.
Financial Description
|
Authorized Capital(KRW) |
200,000,000 |
|
Paid-Up Capital(KRW) |
50,000,000 |
|
Total Issues Shares |
10,000 |
Products, Technologies, Services Description
|
Main Products & Services |
Medicine for Injection |
Trade Partners & Competitors
|
Competitors |
HIGH TECH
PHARM. CO., LTD. 576-1,
SEONGBON-RI, DAESO-MYEON, EUMSEONG-GUN, CHUNGCHEONGBUK-DO, KOREA TEL:+82-43-883-0012 FAX:+82-43-883-0014 HANSEO CHEM
CO., LTD. 2-DANJI,
POSEUNG NATIONAL INDUSTRIAL COMPLEX, 1206-14, WONJEONG-RI, POSEUNG-EUP,
PYEONGTAEK-SI, GYEONGGI-DO, KOREA TEL:+82-31-682-8655 FAX:+82-31-682-8656 DAEBONG LS
CO., LTD. 122B-9L, NAMDONG
INDUSTRIAL COMPLEX, 692-8, GOJAN-DONG, NAMDONG-GU, INCHEON, KOREA TEL:+82-32-817-8800~7 FAX:+82-32-817-8808 |
Sales by Region
(Activity & Markets)
The Subject deals
with the companies in USA, Germany, Netherlands, Australia, New Zealand, China,
Taiwan, Vietnam and Philippines.
Court Action
Not Available.
News Clipping
---
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.45.21 |
|
UK Pound |
1 |
Rs.74.31 |
|
Euro |
1 |
Rs.64.40 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.